Search

Search Constraints

You searched for: Author/Creator Leinenbach, Andreas

Search Results

1. [P4–468]: PROGRESS ON THE DEVELOPMENT OF CERTIFIED REFERENCE MATERIALS FOR Aβ1–42. (1st July 2017)

2. First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays. Issue 11 (4th August 2020)

3. Glycosylation of recombinant rabbit immunoglobulins influences protease susceptibility as shown by comprehensive mass spectrometric glycan analysis. (5th February 2021)

4. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness. Issue 3 (March 2019)

5. Mass Spectrometry–Based Candidate Reference Measurement Procedure for Quantification of Amyloid-β in Cerebrospinal Fluid. (1st July 2014)

7. P4‐705: TOWARD RE‐CALIBRATION OF COMMERCIAL IMMUNOASSAYS USING CERTIFIED REFERENCE MATERIALS FOR Aβ42 IN HUMAN CEREBROSPINAL FLUID. (1st July 2019)

8. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β‐amyloid (1–42) in human cerebrospinal fluid. Issue 5 (7th November 2015)

9. Ultra‐performance liquid chromatography‐tandem mass spectrometry method for analysis of tau in human cerebrospinal fluid without the need of immunocapture: Biomarkers (non‐neuroimaging) / Method development and/or quality control. (7th December 2020)